** Shares of biotech firm Humacyte HUMA.O down 23.5% to $2.20 post-market after stock offering news
** Durham, North Carolina-based firm announces proposed stock offering without disclosing deal size
** Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury
** TD Cowen, Barclays and BTIG jt bookrunners
** With ~122.65 mln shares outstanding, co has ~$353 mln market cap, per LSEG data
** HUMA shares finished Tuesday's session down 13.4% at $2.88. YTD, stock down 43%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.